Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

6.635 -0.055 (-0.82%)
Streaming Delayed Price Updated: 11:49 AM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For May 6, 2025
Via Benzinga
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For February 25, 2025
Via Benzinga
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Biotech Investing: How PRV’s Can Unlock Major Opportunities (OSTX, DAWN, SWTX, PTCT)
Via AB Newswire
Exposures Product Safety
Biotech Investing: How PRVs Can Unlock Major Opportunities
Biotech Investing: How PRVs Can Unlock Major Opportunities 
Via News Direct
Exposures Product Safety
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
Via InvestorPlace
Topics Economy
Exposures Economy
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Sale of Priority Review Voucher for $108 Million
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.